MNTA is staring to move if I were TEVA mgt I would run and make a play before Mylan or another big Generic goes for it, someone will mark my words!!
People who bought Teva many years ago have doubled their money so many will sell and take their gains because of the uncertainties of this proposed Mylan merger. At $82.00 a share, Teva would be paying too much for Mylan.
Looks like TEVA will just take VVUS out . 500 Million would most likely do it . being a 100% premium for VVUS shareholders. Seems like time is now.
Sentiment: Strong Buy
One TEVA big benefit is the cutting of coast bozo.
I agree with you, TEVA is going down the drain.
I see Teva is getting nervous about their future and that was a desperate and ridiculous bid for Mylan's shares, about $10 bill short of what Analyst were predicting.
Mylan would be wise to run and make a play for MNTA right now! This would help them consolidate there strategy of eating into Teva's profits and gaining the Pancreatic Cancer drug platform that is Fast tracked and Oprhan designated by the FDA. Multiple applications for the compound could lead to Lung, blood and various other devistating cancers with little hope. MNTA possesses the technology and is moving ahead and forging an excellent future for themeselves!!
I am in and adding to MNTA position up to $25 as I see this one flying very soon. Mylan might make a bid to gain earlier entrance with COPAXONE and run at TEVA's profits with vigor!!
Today's news of the penalty agreement was the largest ever for such and will put a dent in earnings, significantly. Ouch!
Sounds like a good fit. It was not mentioned but the courts have indicated that the Copaxone 20 patent does not expire til Sept this year. Thus this gives TEVA some time to encourage migration to the 40 Copaxone.
Good discussion you guys! A couple of thoughts: Mylan is a stretch, I agree. The bump up on this merger has already disappeared and Teva down 4.5 % in Israel Sunday according to bloomberg. So we are back to negative sentiment over copaxone patent expiration as we have been for years. And it is no longer as "baked in" as it was at $50 ps. And a generic has now been approved.
But what if teva undercut the generic versions price for the 20ml dose or matched price, kept the 40ml price reasonable, and maintained market share at a slightly lower margin.
Then made an acquisition or two ( ATRS) that is not adversarial, win/win.
I agree earning should be great. I am looking to buy more on any overreaction. GLTA
Personally I think Teva will acquire Antares Pharma (ATRS) due to the fact that Teva will be using Antares injectors in four products including the EPI Pen which is likely to receive an AB rating. Teva will be spending a lot of money for injectors and it will certainly be cheaper for them to own the company. The merger would also benefit future drug endeavors. Time will tell.
Sentiment: Strong Buy
Good point regarding the 20 to 40 migration. On the MYL possibility, I don't think it will happen. The MYL poison pill is destructive to TEVA and there is so much overlap. To nullify the poison pill the deal would have to considered a friendly one by MYL. It was speculated that getting merger approval would be very tough and if permitted it would be at great cost. I tend to agree. However TEVA is on a buying binge, I believe, and just wonder who would be a great fit at a reasonable price.
It seems that the market has reacted in a knee jerk fashion both to the advent of generic 20mg Copaxone and the rumors regarding Mylan (not gonna happen). The bottom line is that TEVA has moved a very substantial amount of 20 mg users over to 40 mg. The 40 mg dose is patent protected until 2030. Yes, it may be challenged in 2017, but look for a long battle over it. I would hold tight until the earnings call, when hopefully updated figures regarding the 40 mg dose will be made public.